| Name | Title | Contact Details |
|---|
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.
HyHealth is a Toledo, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
North River Village is a Tuscaloosa, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Canadian Aboriginal AIDS Network is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enjoy and support protected local lands, where people and nature connect and thrive. Join POST for a hike, film screening or other event—or become a donor!